The central paradox of GLP-1 therapy for obesity is that success creates its own access problem. A patient who starts semaglutide or tirzepatide at a BMI of 35 and achieves a BMI of 27 through treatment has, by most clinical measures, responded beautifully. But BMI 27 may fall below the plan's eligibility threshold for GLP-1 coverage — BMI 30 without comorbidity, or BMI 27 with at least one qualifying comorbidity. At reauthorization, the payer asks a question that sounds reasonable but is clinically fraught: why does this patient still need the drug if they are no longer obese?
The answer, supported by clinical trial data, is that GLP-1–mediated weight loss is not self-sustaining after discontinuation. But the documentation burden falls on the prescriber and the access team, and payers vary widely in how they handle BMI thresholds at reauthorization.
This article is for manufacturer hub teams, field reimbursement specialists, provider-office access coordinators, and payer strategy teams who need to understand how GLP-1 reauthorization works when the patient's BMI has dropped below the original threshold, and what evidence preserves continuation coverage.
The clinical evidence: what happens when GLP-1 therapy stops
The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, documented that patients who stopped semaglutide 2.4 mg after 68 weeks regained approximately two-thirds of their lost weight within one year. The SURMOUNT-4 trial, published in JAMA in December 2023, showed similar results for tirzepatide: patients randomized to switch to placebo after 36 weeks of tirzepatide treatment regained a mean of 14.0% of their body weight over the subsequent 52 weeks, while those who continued tirzepatide lost an additional 5.5%.
A 2026 Lancet eClinical Medicine systematic review of GLP-1 cessation outcomes confirmed that weight regain is rapid, substantial, and near-universal. Most regain occurs in the first three months after discontinuation. Patients who stop GLP-1 therapy typically retain only about 40% of their on-treatment weight loss at one year post-cessation.
The Institute for Clinical and Economic Review (ICER) addressed this directly in its December 2025 Final Evidence Report on semaglutide and tirzepatide for obesity. ICER recommended that payers "use a patient's starting weight, not current weight, as the basis for judging whether further treatment is necessary" because "clinical trial data demonstrate a high likelihood of weight regain after discontinuation in most patients."
This evidence base is the foundation for every reauthorization argument after BMI drops below threshold. The clinical reality is that the patient's current BMI reflects ongoing pharmacotherapy, not a cured state.
How payers handle BMI at reauthorization
Payer policies on BMI thresholds at GLP-1 reauthorization fall into three broad categories:
Category 1: Starting BMI controls eligibility
Some payers anchor eligibility to the patient's BMI at the time of therapy initiation, not the current BMI. Under this approach, a patient who started at BMI 35 and now has BMI 27 remains eligible for continuation because the qualifying condition (obesity, BMI ≥ 30) was present at the start of treatment.
The Medicare GLP-1 Bridge demonstration, launching July 1, 2026, explicitly uses starting BMI. CMS's published FAQ for beneficiaries states: "If a beneficiary initiated GLP-1 therapy in September 2024 with a body mass index (BMI) of 37 and has a BMI of 34 at the time of a July 2026 prior authorization request, the prescribing provider should attest that the beneficiary met the BMI ≥ 35 criterion at the time therapy was initiated." This confirms that CMS evaluates eligibility at initiation, not at reauthorization.
Express Scripts' EncircleRx program, which administers GLP-1 coverage for several Blue Cross Blue Shield plans in 2026, similarly uses the documented BMI at the time the patient started GLP-1 therapy. Harvard University's GLP-1 coverage FAQ, published October 2025, confirms: "If you are already taking one of these weight loss medications, the new required coverage review will look at your documented BMI and weight-related health issues at the time you started taking the medications."
Category 2: Current BMI must continue to meet threshold
A minority of payers require the patient's current BMI to remain at or above the eligibility threshold at each reauthorization cycle. Under this approach, a patient who drops from BMI 35 to BMI 27 on Wegovy may face a coverage denial at reauthorization because their current BMI no longer meets the plan's BMI ≥ 30 criterion (without comorbidity) or BMI ≥ 27 criterion (with comorbidity).
UnitedHealthcare's commercial weight-loss PA notification policy, updated February 2026, requires ≥ 5% weight loss from baseline body weight for Zepbound reauthorization, and ≥ 10% weight loss from baseline for Wegovy injection reauthorization (for patients without cardiovascular indication). While this focuses on weight-loss response rather than BMI threshold directly, a patient whose BMI drops from 35 to 27 (approximately a 23% weight reduction) would easily meet these thresholds — but a patient who drops from 32 to 29 (approximately a 9.4% reduction) might fall short of the Wegovy ≥ 10% requirement.
This approach is clinically problematic because it penalizes therapeutic success. It also creates a perverse incentive for patients to regain weight to maintain coverage. Access teams encountering this policy should be prepared to file appeals with supporting evidence:
- The STEP 1 extension and SURMOUNT-4 data on weight regain after cessation
- The patient's documented comorbidity status, which may independently qualify them at BMI ≥ 27
- The prescriber's clinical judgment that discontinuation would result in clinically significant weight regain
Category 3: Hybrid approaches
Many payers use a hybrid model: starting BMI qualifies the patient for initial authorization, but reauthorization may require documentation of continued clinical benefit (weight maintenance, comorbidity improvement, cardiometabolic risk reduction) even if current BMI has dropped below threshold. This is the most common approach among commercial plans in 2026.
Under hybrid policies, the reauthorization package should include:
| Element | Purpose |
|---|---|
| Documented starting BMI | Confirms initial eligibility |
| Current BMI and weight trend | Demonstrates response or maintenance |
| Comorbidity status at initiation and currently | May independently support coverage at BMI 27–29.9 |
| Prescriber attestation of expected regain with discontinuation | Clinical necessity argument |
| Lifestyle modification participation documentation | Ongoing plan requirement |
Comorbidity documentation as a safety net
For patients whose BMI has dropped below 30 but remains at or above 27, the comorbidity pathway may preserve coverage. Most plans that use a BMI 27 threshold require at least one weight-related comorbidity:
- Hypertension
- Type 2 diabetes
- Dyslipidemia
- Obstructive sleep apnea
- Cardiovascular disease
- Non-alcoholic fatty liver disease (NAFLD) / MASH
- Osteoarthritis
- Polycystic ovary syndrome
The key operational point is that comorbidities must be documented with diagnosis codes, not just mentioned in clinical notes. A patient whose BMI has dropped from 35 to 27 but who still carries diagnosis codes for hypertension (I10) and obstructive sleep apnea (G47.33) remains eligible under the BMI ≥ 27 with comorbidity pathway for most plans.
Access teams should proactively request comorbidity documentation at the start of therapy, not wait until reauthorization. Many patients who qualified at BMI ≥ 30 without comorbidity documentation will need that documentation if their BMI drops into the 27–29.9 range during treatment.
Medicare-specific considerations
Medicare Part D (covered uses)
Medicare Part D plans cover GLP-1 drugs for type 2 diabetes, cardiovascular risk reduction (Wegovy), and obstructive sleep apnea (Zepbound). For these covered uses, BMI-based eligibility is not the primary criterion; diagnosis-specific criteria apply. Reauthorization for diabetes or cardiovascular indications follows the plan's standard renewal process and is generally not BMI-dependent.
Medicare GLP-1 Bridge (obesity)
The Medicare GLP-1 Bridge demonstration, operating July 1, 2026, through December 31, 2027, covers GLP-1 drugs for obesity. CMS's published clinical criteria require:
- BMI ≥ 35 at the time of therapy initiation (a higher threshold than the commercial BMI ≥ 30 standard)
- OR BMI ≥ 30 at initiation with at least one qualifying comorbidity: hypertension, type 2 diabetes, dyslipidemia, or a composite of cardiometabolic risk factors
CMS has confirmed that eligibility is assessed at the time of therapy initiation, not at reauthorization. This means a Bridge participant who started at BMI 36 and drops to BMI 28 remains eligible for continuation under the demonstration.
However, the Bridge operates through Humana as the single central processor, and the PA form (expected to be published in June 2026) may require the prescriber to attest to both the starting BMI and the ongoing clinical rationale for continuation. Access teams should prepare documentation packages that include both elements.
BMI below threshold after Bridge enrollment
A patient who enrolls in the Bridge at BMI 36, responds to therapy, and reaches BMI 28 may face questions at the annual Bridge reauthorization (if applicable — the demonstration runs only 18 months, so most participants will not face a reauthorization within the demonstration window). If the Bridge ends and the patient transitions to the BALANCE model or another coverage pathway, the reauthorization rules of the new program will apply, and those rules may differ.
Weight-regain risk as a medical-necessity argument
The most effective reauthorization strategy for patients whose BMI has dropped below threshold is to frame weight-regain risk as a medical-necessity argument. The argument structure is:
- The patient had obesity (BMI ≥ 30) at the time of therapy initiation.
- The patient has responded to GLP-1 therapy with clinically significant weight loss.
- Clinical trial evidence demonstrates that GLP-1–mediated weight loss is not self-sustaining after discontinuation (STEP 1 extension, SURMOUNT-4, 2026 Lancet systematic review).
- Discontinuation would result in clinically significant weight regain, likely returning the patient to or above the original BMI within 12 months.
- Continued GLP-1 therapy is medically necessary to maintain the achieved weight loss and prevent recurrence of obesity-related comorbidities.
This argument is strongest when supported by:
- Documented comorbidities that improved during treatment (blood pressure reduction, HbA1c improvement, sleep apnea resolution)
- Prescriber attestation that the patient's response is treatment-dependent, not spontaneous
- ICER's December 2025 recommendation favoring starting-weight–based eligibility assessment
How hub and access teams should prepare
At therapy initiation
- Record BMI with a measured weight (not patient-reported)
- Document all qualifying comorbidities with ICD-10 codes, even if BMI ≥ 30 makes comorbidities unnecessary for initial authorization
- Capture baseline metabolic labs (HbA1c, lipid panel, blood pressure)
- Note the plan's reauthorization schedule (6 months, 12 months, or at each fill)
During treatment
- Track BMI trajectory but do not flag BMI reduction as a coverage concern unless the plan uses current-BMI eligibility
- At each visit, update comorbidity documentation, especially if new diagnoses have emerged
- Maintain a weight trend chart for inclusion in reauthorization submissions
At reauthorization
- Confirm whether the plan uses starting BMI or current BMI for eligibility
- Check whether the plan requires a specific weight-loss percentage from baseline for reauthorization (e.g., UnitedHealthcare requires ≥ 5% for Zepbound, ≥ 10% for Wegovy injection)
- Submit a reauthorization package that includes starting BMI, current BMI, comorbidity documentation, prescriber attestation of expected regain, and lifestyle-modification participation
- Aetna's continuation criteria for GLP-1 receptor agonists (BMI 35 pathway) requires that "the patient has had a reduction from their baseline BMI OR the patient has continued to maintain their reduction in BMI from baseline" — this means both starting BMI and current BMI must be documented, but the patient does not need to remain above any threshold
- If the plan uses current BMI and the patient's BMI has dropped below threshold, file the reauthorization with a weight-regain-risk cover letter citing STEP 1 extension, SURMOUNT-4, and ICER recommendation
- If reauthorization is denied, initiate peer-to-peer review with the weight-regain evidence package
Common failure points
Comorbidity not documented at initiation: Patient qualified at BMI ≥ 30, but comorbidities were never coded. At reauthorization with BMI 27, there is no comorbidity pathway. Solution: document all comorbidities at initiation regardless of whether they are needed for initial PA.
PA submission uses current BMI only: Some electronic PA forms default to the patient's current BMI. If the plan uses starting BMI, the access team must override the default and provide the documented starting BMI.
Prescriber does not attest to weight-regain risk: Without a prescriber statement that discontinuation would result in clinically significant weight regain, the payer has no clinical basis to override a BMI-threshold policy.
Reauthorization filed late: If the PA expires before reauthorization is submitted, the patient may face a gap in coverage. For patients near the BMI threshold, a coverage gap is especially risky because weight regain during the gap may complicate the reauthorization argument.
Transition from Bridge to BALANCE without documentation continuity: If the GLP-1 Bridge demonstration ends and the patient transitions to a different coverage model, starting-BMI documentation from the Bridge must carry forward. Access teams should maintain Bridge enrollment records for future reauthorization use.
What to monitor next
BALANCE model BMI criteria: CMS has not yet published final clinical criteria for the BALANCE model, which is expected to replace or extend the Bridge demonstration. Whether BALANCE uses starting BMI or current BMI will determine the reauthorization pathway for millions of Medicare beneficiaries.
State Medicaid BMI policies: Medicaid programs that cover GLP-1 drugs for obesity (13 states as of January 2026 per KFF) vary in their BMI threshold approaches. Several states are expected to update criteria in 2026–2027.
Commercial plan reauthorization tightening: As GLP-1 utilization and costs continue to rise, commercial plans may shift from starting-BMI to current-BMI eligibility at reauthorization. Monitor plan policy bulletins for changes.
ICER follow-up analysis: ICER's December 2025 recommendations may influence payer policy adoption. Access teams should track which payers cite ICER's starting-weight recommendation in their policy documents.
Label expansions and comorbidity pathways: Wegovy's cardiovascular risk reduction indication and Zepbound's obstructive sleep apnea indication create non-BMI-based coverage pathways that may be more robust than BMI-threshold-dependent authorization for certain patients.
This article provides general information about GLP-1 reauthorization and BMI threshold policies. It does not constitute medical advice, reimbursement guidance for any specific patient or plan, or legal guidance. Coverage policies vary by plan, state, and product. Always verify current payer criteria before submitting prior authorization requests.
Sources
- Diabetes, Obesity and Metabolism. "Step 1 Extension: Weight regain after semaglutide cessation." Published 2022. https://dom-online.org
- JAMA. "SURMOUNT-4: Tirzepatide maintenance therapy for obesity." Published December 2023. https://jamanetwork.com/journals/jama/fullarticle/2812773
- Lancet eClinical Medicine. "Trajectory of weight regain after cessation of GLP-1 receptor agonists." Published March 4, 2026. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00043-X/fulltext
- Institute for Clinical and Economic Review (ICER). "Semaglutide and Tirzepatide for Obesity: Final Policy Recommendations." Published December 16, 2025. https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Policy-Recommendations_For-Publication_121625.pdf
- CMS. "Information for Medicare Beneficiaries: Medicare GLP-1 Bridge." Updated 2026. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-medicare-beneficiaries
- Harvard University Benefits. "GLP-1 2026 Clinical Changes and Coverage Requirements FAQs." Published October 2025. https://harvie.harvard.edu/sites/g/files/omnuum12046/files/2025-10/GLP1_Clinical_Changes_FAQ.pdf
- KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid." Published 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid
- CMS. "CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." Press release. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
- Mercer. "GLP-1 Considerations for 2026: Your Questions Answered." https://www.mercer.com/en-us/insights/us-health-news/glp-1-considerations-for-2026-your-questions-answered
- Healthline. "GLP-1 Insurance Coverage for Weight Loss: 2026 Guide." https://www.healthline.com/health/drugs/will-my-insurance-cover-glp-1-for-weight-loss
- Aetna. "Weight Loss (BMI 35) GIP-GLP-1 GLP-1 Agonists PA." Pharmacy Clinical Policy Bulletin. https://www.aetna.com/products/rxnonmedicare/data/2024/Weight_Loss_(BMI%2035)_GIP-GLP-1_GLP-1_Agonists_PA_with_Limit_6450-C_UDR_05-2024.html
- UnitedHealthcare. "PA Notification: Weight Loss/Appetite Suppression Medication." Updated February 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
- Massachusetts Group Insurance Commission. "Update on Vida Health Program and GLP-1 Coverage." 2026. https://www.mass.gov/news/update-on-vida-health-program-and-glp-1-coverage
